Please select the option that best describes you:
At what time points during a patient's treatment for metastatic ER+ breast cancer are you checking liquid NGS for endocrine pathway alterations?
Given that we now have data for PIK3CA (inavolisib, alpelisib), PTEN/AKT/PIK3CA (capivasertib), and ESR1 (elacestrant), when do you look for these alterations? Do you check in specific circumstances or at all phases of progression?
Answer from: Medical Oncologist at Community Practice
Traditionally, liquid NGS testing for PIK3CA, PTEN/AKT/PIK3CA, and ESR1 alterations has been performed at discrete clinical decision points, primarily at progression on endocrine therapy or when considering targeted agents.
Currently, I order NGS at disease onset, even for those who do not fit INAV...
Sign in or Register to read more